[go: up one dir, main page]

WO2012076832A1 - Suppositoires contenant de la rifaximine - Google Patents

Suppositoires contenant de la rifaximine Download PDF

Info

Publication number
WO2012076832A1
WO2012076832A1 PCT/GB2011/000786 GB2011000786W WO2012076832A1 WO 2012076832 A1 WO2012076832 A1 WO 2012076832A1 GB 2011000786 W GB2011000786 W GB 2011000786W WO 2012076832 A1 WO2012076832 A1 WO 2012076832A1
Authority
WO
WIPO (PCT)
Prior art keywords
rifaximin
pharmaceutical composition
suppository
composition according
suppositories
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/000786
Other languages
English (en)
Inventor
Shrinivas Madhukar Purandare
Geena Malhotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of WO2012076832A1 publication Critical patent/WO2012076832A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a pharmaceutical composition comprising an antibacterial drug for rectal or vaginal application and a process for preparing such pharmaceutical composition.
  • the invention relates to a medicated pharmaceutical composition which is capable of releasing the medicament evenly over the walls of the vaginal or rectal cavity.
  • Rifaximin is a semisynthetic antibiotic belonging to the rifamycin class of antimicrobial drugs exhibiting in vitro activity against Gram-positive, Gram-negative and anaerobic bacteria. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis.
  • RNA ribonucleic acid
  • Rifaximin is chemically named as[(25,16Z,18E,205,21 1 S,22 ?,23i?,24/?,25 ⁇ ,265',27 > S,28E)-5,6,21 ,23,25- pentahydroxy-27-methoxy-2,4, 11 ,16,20,22,24,26-octamethyl-2,7 (epoxypentadeca- [1 ,11 , 13]trienimino)benzofuro [4,5-e]pyrido[ 1 ,2-a]-benzimida-zole 1 , 15(2H)-dione,25 - acetate].
  • Rifaximin has the following chemical formula.
  • Rifaximin has been indicated for the treatment of traveler's diarrhea caused by non-invasive strains of Escherichia coli, a micro-organism which is not able to penetrate into gastrointestinal (GI) mucosa and therefore remains in contact with gastrointestinal fluids.
  • Rifaximin is highly effective in preventing and treating traveler's diarrhea, with fewer side effects and a low risk of developing antibiotic resistance.
  • Rifaximin is also approved for the treatment of pathologies whose etiology is in part or totally due to intestinal acute and chronic infections sustained by Gram-positive and Gram- negative bacteria, with diarrhea syndromes, altered intestinal microbial flora, summer diarrhea-like episodes, traveler's diarrhea and enterocolitis, pre- and post- surgery prophylaxis of the infective complications in gastro intestinal surgery; and hyperammonaemia therapy as coadjutant.
  • Rifaximin is a poorly water-soluble and minimally absorbed ( ⁇ 0.4%) drug with in vitro activity against enteric Gram-negative bacteria including enteric pathogens. [Gerard L et al, Rifaximin, a non-absorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Review of Anti-infective therapy, 3(2), 201-21 1 , (2005)].
  • Rifaximin has been described to be endowed with an antibacterial activity similar to the activity of rifampin [Venturini A. P. and Marchi E., Chemiotherapia, 5 (4), 257-256, (1986)].
  • its mechanism of action differs from rifampin in that it is not absorbed through the systemic route after oral administration [Venturini A. P., Chemotherapy, 29, 1-3, (1983) and Cellai L. et al, Chemiotherapia, 3, (6), 373-377, (1984)] due to the zwitterionic nature of the compound, which cannot be absorbed by the gastrointestinal tract [Marchi E. et al, Journal of Medicinal Chemistry., 28, 960-963, (1985)].
  • rifaximin has no systemic absorption, which poses a challenge to formulate suitable formulations of rifaximin.
  • Rifaximin is currently available as tablets, granules for oral suspension and ointment, marketed in Europe and U.S.A. and in many other countries. Tablets, for example are currently marketed at the dosage of 200 mg for traveler's diarrhea under the brand name Xifaxan®.
  • US5314904 discloses therapeutic use of rifaximin in the treatment of vaginal infections, in particular bacterial vaginosis.
  • the patent discloses that the composition can be administered topically in the form of foam, a cream, a gel, a vaginal ovule or vaginal capsule.
  • US6140355 discloses a pharmaceutical composition for topical application on the vagina the composition being in the form of foam, or a cream.
  • US5352679 discloses a pharmaceutical composition for treatment of gastric dyspepsia by oral administration of rifaximin, the composition being in the form of a tablet, a capsule, a sugar coated tablet, granules or a syrup.
  • US5886002 discloses a pharmaceutical composition of rifaximin for treatment of diarrhoea from cryptosporidiosis, the composition being in the form of a tablet, a capsule, a sugar coated tablet, granules or a syrup.
  • CN 150914 discloses a rifaximin spray for treating bacterial rhinitis and inflammation of the respiratory tract.
  • WO2009008005 discloses a multilayer tablet composition of rifaximin wherein one layer is an immediate release and the other is controlled release. Further, as rifaximin exhibits a lower systemic absorption, there is yet a need to formulate rifaximin in a suitable dosage form.
  • One such dosage form is suppository. Suppositories are advantageous as they provide local action at the target site and in the case of rifaximin which is intestine.
  • the patient is exposed to higher doses of the drug than are actually required for successful treatment.
  • the cost of the therapy is also unnecessarily increased due to the use of excess medicament.
  • the stability of the drug be maintained during storage by insuring that the respective components of the suppository do not experience chemical or physical changes or that the proteins do not get decomposed, denatured, aggregated or reduces activity during storage.
  • the suppository should not only melt rapidly at body temperature within body cavities but also should not soften during summer or harden during winter nor absorb moisture from the ambient air.
  • the suppository should withstand prolonged storage without causing putrefaction, deterioration, discoloration, mold growth or the denaturing of proteinaceous additives such as natural gelatin. Further the suppository should permit rapid release of the drug, should not contain substances that irritate the mucosa or produce local irritation, should provide a comfortable feel during use.
  • a suppository is also advantageous in hostile patients, in elderly patients who cannot swallow oral medication, bed ridden patients, unconscious patients, post operative patients who cannot be administered oral medication, or in infants.
  • suppositories While manufacturing suppositories one has to ensure that the drug is dispersed uniformly in the base and the suppositories have good emulsion stability. Further, the suppositories should be manufactured by a simple process and should also be reproducible at an industrial scale.
  • the pharmaceutical formulation design must be performed with full consideration as to whether the suppository is intended to be administered for systemic action or local action and also whether the site of administration is at the rectum or vagina. For instance, if the site of administration is the rectum, the ease of absorption of the drug is a dominant factor and if the site of administration is the vagina, factors such as the possible effect of the suppository on the fetus and the feel of use which depends on the possibility of the base of remaining in the vagina are to be considered.
  • the object of the present invention is to provide a pharmaceutical composition comprising rifaximin having improved stability during storage.
  • Another object of the present invention is to provide a process for preparing a pharmaceutical composition comprising rifaximin.
  • Yet another object of the present invention is to provide a method for treatment and/or prevention of colonic diseases which comprises administering a pharmaceutical composition comprising rifaximin.
  • a pharmaceutical composition comprising rifaximin or a pharmaceutically acceptable salt, solvate, derivative, hydrate, enantiomer, polymorph, complex, or mixtures thereof.
  • a pharmaceutical composition comprising rifaximin or a pharmaceutically acceptable salt, solvate, derivative, hydrate, enantiomer, polymorph, complex or mixtures thereof wherein the rifaximin may or may not be in the nanosize range.
  • a process for preparing a pharmaceutical composition comprising rifaximin or a pharmaceutically acceptable salt, solvate, derivative, hydrate, enantiomer, polymorph, complex or mixtures thereof wherein rifaximin may or may not be in a nanosize range.
  • a method of treatment and/or prevention of colonic diseases which comprises administering a pharmaceutical composition comprising rifaximin or a pharmaceutically acceptable salt, solvate, derivatives hydrate, enantiomer, polymorph, complex or mixtures thereof wherein rifaximin may or may not be in a nanosize range.
  • Suppository as a dosage form is smaller than any other medicinal preparations for internal use. Particularly, it has an advantage that it can be easily dosed to children. Further, when the drug is administered in the dosage form of suppository, the drug is not available for any decomposition by acid, alkali, digestive enzymes and the like and hence does not cause gastro enteric troubles. Suppositories can avoid decomposition of drugs by acid or enzyme in gastrointestinal tract when the drugs are orally administered. They can also avoid irritation, stimulation to the gastrointestinal mucosa which is caused by direct contact of drugs with the mucosa.
  • suppositories are physiologically less affected by such factors as variations of pH in gastrointestinal tract, the gastric empty rate, mobility of gastrointestinal tract, mutual actions between food components, and the like. Moreover, where the delivery of a medicine in the form of injection may cause serious ill effects, these ill effects can be minimized by a local delivery in the form of a suppository only to the affected portion.
  • the inventors of the present invention have developed compositions for suppositories which sustain a melting point higher than the body temperature under dry storage conditions but, when inserted into body cavity, become moist due to the moisture in the cavities and thus quickly melt or gel at the body temperature.
  • Rifaximin is a poorly water-soluble drug exhibiting minimal absorption.
  • Rifaximin is also characterized by negligible systemic absorption, due to its chemical and physical characteristics.
  • the desired therapeutic effect is achieved by diffusion of rifaximin throughout the vaginal or rectal cavity and by preventing the liquefied suppository from flowing out of the vaginal or rectal cavity.
  • the availability of rifaximin is thus increased by the resultant increase in the adhesion properties and the extension of the time during which the rifaximin resides in the vaginal or rectal cavity.
  • the unique combination of ingredients results in a homogeneous medicated pharmaceutical composition which is capable of distributing rifaximin throughout the vaginal or rectal cavity.
  • rifaximin is used in broad sense to include not only “rifaximin” per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable complexes, etc.
  • the pharmaceutical composition of the present invention may comprise rifaximin in a crystalline form, amorphous form, or may be nanosized, or may be present in the form of a complex of cyclodextrin and PVP or mixtures thereof. According to one embodiment of the present invention, the rifaximin may be present in the nanosize form.
  • the pharmaceutical composition of the present invention is in the form of a suppository.
  • Nanonization of hydrophobic or poorly water-soluble drugs generally involves the production of drug nanocrystals through either chemical precipitation (bottom-up technology) or disintegration (top-down technology). Different methods may be utilized to reduce the particle size of the hydrophobic or poorly water soluble drugs. [Huabing Chen et al., discusses the various methods to develop nanoformulations in "Nanonization strategies for poorly water-soluble drugs," Drug Discovery Today, Volume 00, Number 00, March 2010].
  • Nanosizing leads to increase in the exposure of surface area of rifaximin particles leading to an increase in the rate of dissolution.
  • the present invention thus provides a pharmaceutical composition, comprising rifaximin wherein rifaximin is in the nanosize range.
  • the nanoparticles of the present invention can be obtained by any of the process such as but not limited to milling, precipitation, homogenization and the like.
  • the pharmaceutical composition of the present invention may comprise rifaximin having an effective particle size range of less than 2000nm, preferably below lOOOnm.
  • the process of milling comprises dispersing rifaximin particles in a liquid dispersion medium in which rifaximin is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of rifaximin to the desired effective average particle size.
  • the pharmaceutical composition according to the present may comprise 200mg of rifaximin.
  • the dose of the pharmaceutical composition of the present invention may be varied as appropriate for such factors as the frequency of administration per day, the content of rifaximin in a single suppository and the severity of the disease to be treated.
  • the present invention thus provides a pharmaceutical composition comprising rifaximin, one or more suppository vehicles and optionally other pharmaceutically acceptable carriers.
  • present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising rifaximin, one or more suppository vehicles and optionally other pharmaceutically acceptable carriers in a soft capsule.
  • the invention encompasses two embodiments of suppository formulation
  • the rifaximin is dispersed within a solidified suppository vehicle.
  • any excipients may be dispersed within the solidified suppository vehicle along with the rifaximin. Suitable excipients include surfactants, sucrose fatty acid esters, stabilizers, pH adjusting agents, isotonic agents, viscosity-adjusting agents, preservatives, as described below.
  • additional active ingredient may be dispersed in the solidified suppository vehicle.
  • the rifaximin and a suppository vehicle are disposed within a soft capsule, which is preferably a gelatin capsule.
  • any excipients may be dispersed within the suppository vehicle along with the rifaximin. Suitable excipients include surfactants, sucrose fatty acid esters, stabilizers, pH adjusting agents, isotonic agents, viscosity-adjusting agents, preservatives, as described below.
  • Suitable excipients include surfactants, sucrose fatty acid esters, stabilizers, pH adjusting agents, isotonic agents, viscosity-adjusting agents, preservatives, as described below.
  • additional active ingredient may be dispersed in the suppository vehicle.
  • the suppository vehicle is typically not solidified and may be a liquid.
  • the suppository vehicle may be aqueous or fatty.
  • the invention provides a soft capsule comprising rifaximin one or more suppository vehicles and optionally other pharmaceutically acceptable carriers, wherein the capsule shell may comprise gelatin, glycerol, sorbitol solution, plant polysaccharides or their derivatives like carrageenans and modified forms of starch and cellulose.
  • the suppository vehicle will be selected to be suitable as solid vehicle, whereas in the second embodiment it will be selected to be suitable for use within a capsule.
  • the suppository vehicle comprises a suppository base and certain adjuvants and additives suitable for making such formulations.
  • the suppository base may be an aqueous base that has hydrophilic properties or a fatty base material that has hydrophobic properties.
  • the fatty based (oleaginous base) suppositories used in the present invention include materials that are commonly used for making suppositories such as cocoa butter, palm oil, coconut oil, lard; waxes, such as lanolin and vasoline; fatty acids, such as, oleic, stearic, and lauric acids, polyethylene glycols or mixtures of mono, di, and triglycerides of fatty acids of C i o to C 2 o chain length.
  • Suppocire AI A, B, C, D, AS2, BS2, AT, AS2X, BS2X, CS2X (Semi-synthetic glycerides- Multi purpose vehicles), Suppocire AM, AM, BM, BCM, CM, DM (Semi-synthetic glycerides- Low Reactivity Vehicles), Suppocire AIML, AML, BML (Semi-synthetic glycerides- Low Reactivity Vehicles Compatible With Large Amounts Of Powders), Suppocire AP, BP, CP, DP (Saturated polyglycolysed glycerides- Absoprtion Enhancers), Suppocire NA 0, NAI 10, NA 10, NAS 10, NA 15, NAIS 10, NCS 10 (Semi-synthetic glycerides- Low Reactivity Vehicles), Suppocire NAI, NA
  • Witepsol W 25 (Hydrogenated Coco-Glycerides), Witepsol W 31 (Hydrogenated Coco-Glycerides), Witepsol W 32 (Hydrogenated Coco-Glycerides), Witepsol W 35 (Hydrogenated Coco-Glycerides), Witepsol W 45 (Hydrogenated Coco-Glycerides), Witepsol S 51 (Hydrogenated Coco- Glycerides + Ceteareth-25 + Glyceryl Ricinoleate ), Witepsol S 52, Witepsol S 55 (Hydrogenated Coco-Glycerides + Ceteareth-25 + Bees Wax), Witepsol S 58 (Hydrogenated Coco-Glycerides + Ceteareth-25 + Glyceryl Ricinoleate), Witepsol E 75 (Hydrogenated Coco-Glycerides + Bees Wax), Witepsol E 76 (
  • the aqueous base suppositories that can be used in the present invention include polymers of ethylene oxide, e.g., polyethylene glycols (PEG). These polymers of PEG vary in molecular weight, from 200-8000 g/mol. Also as the molecular weight of PEG increases, the hardness of PEG also increases. By combining different proportions of PEG polymers, a suppository base can be made to desired consistency and characteristics. Glycerinated gelatin is also used in this type of suppositories, but mostly as the base for vaginal suppositories. Other types of bases can also be used, such as Polysorbate. The aqueous base can be used alone or used in combination with other base materials to produce suppositories of varying consistency and solubility.
  • PEG polyethylene glycols
  • the pharmaceutical composition of the present invention may further comprise emulsifiers.
  • Emulsifiers assure good stability in emulsification and provide satisfactory shape upon solidification of the suppository.
  • emulsifiers include but are not limited to nonionic surfactants, anionic surfactants, cationic surfactants and amphoteric surfactants or mixtures thereof.
  • Suitable nonionic surfactants may comprise sorbitan fatty acid esters, glycerol fatty acid esters, glycerol (covering the glycerin and cone, glycerin listed in the Pharmacopeia of Japan), decaglycerin fatty acid esters, polyglycerin fatty acid esters, propylene glycol fatty acid esters, pentaerythritol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyethylene glycol fatty acid esters, sucrose fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene phytosterols, polyoxyethylene phytostanols, polyoxyethylene polyoxypropylene glycol, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene lanolin, polyoxyethylene lanolin alcohol, beeswax derivatives, polyoxyethylene al
  • Suitable anionic surfactants may comprise alkyl sulfates, polyoxyethylene alkyl ether sulfates, N-acylamino acid or salts thereof, and polyoxyethylene alkyl ether phosphates or mixtures thereof.
  • Suitable cationic surfactants may comprise alkyl ammonium salts and alkylbenzyl ammonium salts or mixtures thereof.
  • Suitable amphoteric surfactants may comprise betaine acetate and lecithin or mixtures thereof.
  • emulsifier The greater the amount of the emulsifier, the higher is the stability in emulsification, which hence suits manufacturing purposes; however, if too much emulsifier is employed, air bubbles are prone to occur during the preparation of the pharmaceutical composition and the solidified pharmaceutical composition will involve air entrapment and shrinkage to cause nonuniformity in properties and lower hardness. Excessive emulsifier may also be a problem with the safety of pharmaceuticals. Further, depending on the type of the emulsifier and its combination with the medicinal component, excessive emulsifier may reduce the releasability of the drug, thereby deteriorating the performance of the suppository;
  • the pharmaceutical composition of the present invention may further comprise sucrose fatty acid esters which are generally referred to as sugar esters are monoesters, diesters, triesters constituted of sucrose and one or more fatty acids or mixtures thereof.
  • sucrose fatty acid esters which are generally referred to as sugar esters are monoesters, diesters, triesters constituted of sucrose and one or more fatty acids or mixtures thereof.
  • the pharmaceutical composition of the present invention may further comprise stabilizers such as among amino acids or salts thereof, proteins and sugars.
  • amino acids include basic amino acids such as arginine and lysine, as well as acidic amino acids such as glutamic acid and aspartic acid; proteins include gelatin and albumin; and sugars include disaccharides such as sucrose and maltose, as well as sugar alcohols such as mannitol and sorbitol.
  • Amino acid salts are available in two salt types, one with inorganic acids and the other with organic acids, and either will do if they can be used as pharmaceuticals.
  • the pharmaceutical composition of the present invention may further comprise pH adjusting agents such as but not limited to hydrochloric acid, acetic acid, citric acid, lactic acid or any other suitable acids that can be used in pharmaceutical products.
  • buffer solutions comprising these acids in combination with other salts such as but not limited to sodium chloride, potassium chloride, calcium chloride may be added. If desired, both acids and buffer solutions may be used as pH adjusting agents.
  • the pharmaceutical composition of the present invention may further comprise isotonic agents such as sodium chloride and potassium chloride, antiseptics typified by paraoxybenzoic acid esters such as methyl paraoxybenzoate and propyl paraoxybenzoate.
  • the pharmaceutical composition of the present invention may further comprise viscosity- adjusting agents such as microcrystalline wax, beeswax, paraffin or cetyl palmitate sodium stearate.
  • the pharmaceutical composition of the present invention may further comprise preservatives such as methyl paraben or propyl paraben.
  • the pharmaceutical composition of the present invention may further include antioxidants, coloring agents, fragrances, anti-fissuring agents, additives for adjusting hardness and feel, or any other additives that can customarily be added.
  • the pharmaceutical composition of the present invention may provide immediate and/or modified release such as delayed, sustained, pulsed, controlled, targeted and programmed release.
  • the pharmaceutical composition of the present invention may provide a multilayered suppository having two or more layers with different release rates, or a method of preparing the sustained-release suppository preparation as a suppository having a core and two or more layers with different release rates.
  • the pharmaceutical composition of the present invention may provide as an effervescent pharmaceutical composition of rifaximin for rectal or vaginal administration.
  • composition of the present invention may be administered either rectally or into the vagina and a suitable route should be selected as appropriate for the indicated disease or the object of use as to whether a systemic or local action is desired.
  • the pharmaceutical composition of the present invention may be administered by an applicator for applying medicaments to a body cavity as disclosed, for example, in U.S. Pat. No. 2,007,626 and U.S. Pat. No. 2,105,710.
  • the pharmaceutical composition according to the present invention may further comprise at least one additional active ingredient.
  • Additional active agents may be selected from, but not limited to one or more of antiinflammatory agents, steroids (e.g. corticosteroids), additional antibiotics, anti-fungal agents, anti-viral agents, analgesics, or anti-neoplastic agents.
  • Suitable antibiotics include, but are not limited to, dapsone, chloramphenicol, neomycin, cefaclor, cefadroxil, cephalexin, cephradine, erythromycin, clindamycin, lincomycin, amoxicillin, ampicillin, bacampicillin, carbenicillin, dicl oxacillin, cyclacillin, picloxacillin, hetacillin, methicillin, nafcillin, penicillin, polymyxin, tetracycline, amphotericin-b, candicidin, dermostatin, filipin, fungichromin, hachimycin, hamycin, lucensomycin, mepartricin, natamycin, nystatin, pecilocin, penmycin, azasenne, griseofulvin, oligomycins, neomycin undecylenate, pyrroinitrin, siccanin, tubercid
  • Suitable anitfungal agents include but are not limited to, allylamines such as butenafme, naftifine, imidazoles such as bifonazole, butoconazole, chlordantoin, chlormidazole, cloconazole, clotrimazole, econazole, enilconazole, fenticonazole, flutrimazole, isoconazole, ketoconazole, lanoconazole, miconazole, omoconazole, oxiconazole nitrate, sertaconazole, sulconazole, tioconazole, triazoles such as fluconazole, itraconazole, saperconazole, terconazole, and others such as acrisorcin, amorolfine, biphenamine, bromosalicylchloranilide, buclosamide, calcium propionate, chlophenesin, ciclopirox, cloxyquin, co
  • Antifungal agents may also include, polyenes such as amphotericin-b, candicidin, dermostatin, filipin, fungichromin, hachimycin, hamycin, lucensomycin, mepartricin, natamycin, nystatin, pecilocin, penmycin, azaserine, griseofulvin, oligomycins, neomycin undecylenate, pyrroinitrin, siccanin, tubercidin, viridin, allylamines such as butenafme, naftifine, imidazoles such as bifonazole, butoconazole, chlordantoin, chlormidazole, cloconazole, clotrimazole, econazole, enilconazole, fenticonazole, flutrimazole, isoconazole, ketoconazole, lanoconazole, miconazole, omoconazole,
  • Non-steroidal anti-inflammatory agents include, but are not limited to, aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflum
  • Suitable corticosteroids include but are not limited to, hydrocortisone, i.e., 11 -17- 21- trihydroxypregn-4-ene-3,20-dione or Cortisol, Cortisol acetate, hydrocortisone phosphate, hydrocortisone 21 -sodium succinate, hydrocortisone tebutate, corticosterone, corticosterone acetate, cortisone, cortisone acetate, cortisone 2 IB- cyclopentanepropionate, cortisone phosphate, triamcinolone hexacetonide, dexamethasone phosphate, desonide, betamethasone dipropionate, mometasone furate.
  • Antineoplastic agents may also be included in the pharmaceutical composition of the present invention along with rifaximin which include, but are not limited to, vincristine, vinblastine, vindesine, busulfan, chlorambucil, spiroplatin, cisplatin, carboplatin, methotrexate, adriamycin, mitomycin, bleomycin, cytosine arabinoside, arabinosyl adenine, mercaptopurine, mitotane, procarbazine, dactinomycin (antinomycin D), daunorubicin, doxorubicin hydrochloride, taxol, plicamycin, aminoglutethimide, estramustine, flutamide, leuprolide, megestrol acetate, tamoxifen, testolactone, trilostane, amsacrine (m-AMSA), asparaginase (L-asparaginase), etoposide, and interfer
  • Antiviral agents may also be included in the pharmaceutical composition of the present invention along with the rifaximin which include, but are not limited to, acyclovir, amantadine, azidothymidine, ribavirin and vidarabine.
  • the pharmaceutical composition of the present invention may be prepared by moulding, the process involves that suppository base is melted using the least possible amount of heat, and then the liquid mass so obtained is poured into moulds having the desired nominal capacity.
  • the suppositories produced by moulding are oblong and smooth, and they have a uniform appearance. Melting is intended to provide a uniform distribution of the drug in the base mass.
  • the pharmaceutical composition of the present invention may be prepared by encapsulating the dispersion of rifaximin along with one or more fatty bases in a soft capsule and further drying the soft capsule.
  • the suppositories may be prepared by producing a suppository mixture granulate containing active drug, optionally and other pharmaceutical excipients commonly used and polyethylene glycol, compressing the produced mass to suppositories by a method known per se for the production of tablets.
  • the suppositories may be prepared by hand moulding by rolling the well blended suppository base containing rifaxmin into a desired shape, wherein the suppository base is first grated and kneaded with rifaximin until the resultant mass is plastic and thoroughly blended.
  • the suppositories may also be prepared by compression moulding which process involves forcing a mixed mass of grated suppository base and rifaximin into a special compression mould.
  • the pharmaceutical composition according to the present invention may be used to treat a bacterial infection, e.g., acute hemorrhoidal disease, irritable bowel syndrome, travelers diarrhea, small intestinal anal disease, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, colitis, hepatic encephalopathy, antibiotic associated colitis, and/or diverticular disease
  • a bacterial infection e.g., acute hemorrhoidal disease, irritable bowel syndrome, travelers diarrhea, small intestinal anal disease, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, colitis, hepatic encephalopathy, antibiotic associated colitis, and/or diverticular disease
  • the present invention further provides a method of treatment and/or prevention of colonic diseases, which method comprising administering to a subject in need thereof an effective amount of rifaximin, wherein the rifaximin may or may not be in the nanosize range.
  • rifaximin may or may not be in the nanosize range.
  • Witepsol H 15 was melted at a temperature of about 50-60°C.
  • step (2) The molten mass obtained in step (2) was congealed at a temperature of 36-40°C. 4) The congealed mass was filled in the suppository moulds.
  • Suppocire NA 15 was melted at a temperature of about 50-60°C.
  • step (2) Rifaximin was added to the melted mass obtained in step (1) and further homogenized. 3) The molten mass obtained in step (2) was congealed at a temperature of 36-40°C.
  • Suppocire NA 25 was melted at a temperature of about 50-60°C.
  • step (2) Rifaximin was added to the melted mass obtained in step (1) and further homogenized. 3) The molten mass obtained in step (2) was congealed at a temperature of 36-40°C.
  • Suppocire BM was melted at a temperature of about 50-60°C.
  • step (2) Rifaximin was added to the melted mass obtained in step (1) and further homogenized. 3) The molten mass obtained in step (2) was congealed at a temperature of 36-40°C.
  • Ovicure WL 3264 was melted at a temperature of about 50-60°C.
  • step (2) Rifaximin was added to the melted mass obtained in step (1) and further homogenized. 3) The molten mass obtained in step (2) was congealed at a temperature of 36-40°C.
  • Rifaximin was dispersed with a homogenizer in soyabean oil and hydrogenated castor oil.
  • step (3) The soft gel capsules obtained in step (2) were further dried.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition pharmaceutique contenant de la rifaximine et se présentant sous la forme d'un suppositoire.
PCT/GB2011/000786 2010-12-09 2011-05-23 Suppositoires contenant de la rifaximine Ceased WO2012076832A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3363/MUM/2010 2010-12-09
IN3363MU2010 2010-12-09

Publications (1)

Publication Number Publication Date
WO2012076832A1 true WO2012076832A1 (fr) 2012-06-14

Family

ID=44211947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/000786 Ceased WO2012076832A1 (fr) 2010-12-09 2011-05-23 Suppositoires contenant de la rifaximine

Country Status (1)

Country Link
WO (1) WO2012076832A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2015013591A1 (fr) * 2013-07-26 2015-01-29 Cedars-Sinai Medical Center Procédés de traitement du syndrome du côlon irritable
US20160038468A1 (en) * 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
US9271968B2 (en) 2005-03-03 2016-03-01 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
CN106074433A (zh) * 2016-06-30 2016-11-09 浙江安宝药业有限公司 利福昔明软胶囊药物及其制备方法
US9498442B2 (en) 2010-03-05 2016-11-22 Alfa Wassermann S.P.A. Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
WO2018075730A1 (fr) * 2016-10-21 2018-04-26 Axim Biotechnologies, Inc. Suppositoires comprenant des cannabinoïdes
US10258610B2 (en) 2011-07-29 2019-04-16 Alfasigma S.P.A. Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
US10285944B2 (en) 2005-03-07 2019-05-14 Alfasigma S.P.A. Gastroresistant pharmaceutical formulations containing rifaximin
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
WO2022090490A1 (fr) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Formulations liquides de rifaximine destinées à être utilisées dans le traitement de la drépanocytose

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007626A (en) 1933-04-14 1935-07-09 Vadsco Salcs Corp Capsule applicator
US2105710A (en) 1935-03-28 1938-01-18 Wadel Josef Casing for suppositories
EP0547294A1 (fr) * 1991-12-17 1993-06-23 ALFA WASSERMANN S.p.A. Compositions à base de rifaximine pour le traitement d'infections vaginales
US5352679A (en) 1993-03-23 1994-10-04 Alfa Wassermann S.P.A. Use of rifaximin and pharmaceutical formulations containing it in the treatment of gastric dyspepsia caused by helicobacter pylori
US5886002A (en) 1997-02-14 1999-03-23 Alfa Wassermann S.P.A. Use of rifaximin and of pharmaceutical compositions containing it in the treatment of the diarrhoea from cryptosporidiosis
CN1509714A (zh) 2002-12-25 2004-07-07 天津合益达生物医学技术有限公司 利福昔明喷雾剂
WO2007103448A2 (fr) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Preparation anti-dysfonctionnement rectal de rifaximine
US20080132530A1 (en) * 2003-11-07 2008-06-05 Alfa Wassermann S.P.A. Use of polymorphic forms of rifaximin for medical preparations
WO2009008005A1 (fr) 2007-07-06 2009-01-15 Lupin Limited Compositions pharmaceutiques de rifaximine
WO2010040020A1 (fr) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Méthodes de traitement d’une encéphalopathie hépatique
WO2011050397A1 (fr) * 2009-10-26 2011-05-05 Borody Thomas J Nouvelle polythérapie gastro-résistante

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007626A (en) 1933-04-14 1935-07-09 Vadsco Salcs Corp Capsule applicator
US2105710A (en) 1935-03-28 1938-01-18 Wadel Josef Casing for suppositories
US6140355A (en) 1991-12-17 2000-10-31 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
US5314904A (en) 1991-12-17 1994-05-24 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
EP0547294A1 (fr) * 1991-12-17 1993-06-23 ALFA WASSERMANN S.p.A. Compositions à base de rifaximine pour le traitement d'infections vaginales
US5352679A (en) 1993-03-23 1994-10-04 Alfa Wassermann S.P.A. Use of rifaximin and pharmaceutical formulations containing it in the treatment of gastric dyspepsia caused by helicobacter pylori
US5886002A (en) 1997-02-14 1999-03-23 Alfa Wassermann S.P.A. Use of rifaximin and of pharmaceutical compositions containing it in the treatment of the diarrhoea from cryptosporidiosis
CN1509714A (zh) 2002-12-25 2004-07-07 天津合益达生物医学技术有限公司 利福昔明喷雾剂
US20080132530A1 (en) * 2003-11-07 2008-06-05 Alfa Wassermann S.P.A. Use of polymorphic forms of rifaximin for medical preparations
WO2007103448A2 (fr) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Preparation anti-dysfonctionnement rectal de rifaximine
WO2009008005A1 (fr) 2007-07-06 2009-01-15 Lupin Limited Compositions pharmaceutiques de rifaximine
WO2010040020A1 (fr) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Méthodes de traitement d’une encéphalopathie hépatique
WO2011050397A1 (fr) * 2009-10-26 2011-05-05 Borody Thomas J Nouvelle polythérapie gastro-résistante

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CELLAI L. ET AL., CHEMIOTHERAPIA, vol. 3, no. 6, 1984, pages 373 - 377
DESCOMBE J J ET AL.: "Pharmacokinetic study of rifaximin after oral administration in healthy volunteers", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, vol. 14, no. 2, 1994, pages 51 - 56
GERARD L ET AL.: "Rifaximin, a non-absorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections", EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, vol. 3, no. 2, 2005, pages 201 - 211
HUABING CHEN ET AL.: "Nanonization strategies for poorly water-soluble drugs", DRUG DISCOVERY TODAY, vol. 00, no. 00, March 2010 (2010-03-01)
MARCHI E. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, 1985, pages 960 - 963
VENTURINI A. P., CHEMOTHERAPY, vol. 29, 1983, pages 1 - 3
VENTURINI A. P., MARCHI E., CHEMIOTHERAPIA, vol. 5, no. 4, 1986, pages 257 - 256

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271968B2 (en) 2005-03-03 2016-03-01 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US10703763B2 (en) 2005-03-03 2020-07-07 Alfasigma S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US10285944B2 (en) 2005-03-07 2019-05-14 Alfasigma S.P.A. Gastroresistant pharmaceutical formulations containing rifaximin
US9498442B2 (en) 2010-03-05 2016-11-22 Alfa Wassermann S.P.A. Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
US10258610B2 (en) 2011-07-29 2019-04-16 Alfasigma S.P.A. Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9452157B2 (en) 2012-07-06 2016-09-27 Alfa Wassermann S.P.A Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof
EA028769B1 (ru) * 2012-07-06 2017-12-29 Альфа Вассерманн С.П.А. Фармацевтические композиции, содержащие рифаксимин и аминокислоты, способ их получения и их применение
WO2014006576A1 (fr) * 2012-07-06 2014-01-09 Alfa Wassermann S.P.A. Compositions pharmaceutiques comprenant de la rifaximine et des acides aminés, procédé de préparation et utilisation correspondants
US20160038468A1 (en) * 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
WO2015013591A1 (fr) * 2013-07-26 2015-01-29 Cedars-Sinai Medical Center Procédés de traitement du syndrome du côlon irritable
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
CN106074433A (zh) * 2016-06-30 2016-11-09 浙江安宝药业有限公司 利福昔明软胶囊药物及其制备方法
US10092538B2 (en) 2016-10-21 2018-10-09 Axim Biotechnologies, Inc. Suppositories comprising cannabinoids
WO2018075730A1 (fr) * 2016-10-21 2018-04-26 Axim Biotechnologies, Inc. Suppositoires comprenant des cannabinoïdes
WO2022090490A1 (fr) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Formulations liquides de rifaximine destinées à être utilisées dans le traitement de la drépanocytose

Similar Documents

Publication Publication Date Title
WO2012076832A1 (fr) Suppositoires contenant de la rifaximine
JP4617081B2 (ja) 連続的薬剤送達システム
KR101398648B1 (ko) 리팍시민 직장 기능장애 치료 제제
EP3154529B1 (fr) Comprimé oraux à désintégration rapide contenant des particules lipidiques solides, et procédé de préparation et méthode d'utilisation de celui-ci
AU2010320656B2 (en) Topical foam composition
Narang et al. Sublingual mucosa as a route for systemic drug delivery
ES2355439T3 (es) Parche bioerosionable.
JP2782693B2 (ja) 低温融解性の成形可能な医薬品賦形剤及びこれを用いた投与剤形
CN1343128B (zh) 药物组合物
ES2665464T3 (es) Forma de dosificación oral sólida que contiene microcápsulas sin costuras
EP2444064A1 (fr) Procédé pour fabriquer des formes de dosage de rétention gastrique à multi-particules
ES2292614T3 (es) Formulacion oral de fusion rapida de un inhibidor de ciclooxigenasa-2.
AU4490900A (en) Beta-carboline pharmaceutical compositions
EA010110B1 (ru) Дозированные формы азитромицина с пониженными побочными эффектами
CN104189913A (zh) 包含聚乙烯醇-聚乙二醇接枝共聚物的泡沫干胶片
US20100260835A1 (en) Pharmaceutical composition
MX2013002802A (es) Composicion farmaceutica.
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
JP2013511569A (ja) 局所用泡沫組成物
Gupta et al. Understanding the routes of administration
US20150196488A1 (en) Topical Foam Composition
WO2009141309A1 (fr) Système d'administration de palipéridone
WO2005046651A1 (fr) Capsules remplies de liquide et renfermant de la doxycycline
ES2939889T3 (es) Formulación microgranular novedosa
CN107582541A (zh) 抗耐药菌抗生素微球的脉冲式给药制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11724435

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11724435

Country of ref document: EP

Kind code of ref document: A1